


Viking Therapeutics, Inc. (VKTX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001607678

Viking Therapeutics, Inc. VKTX; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025	
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$591M to \$2.67B assets total assets \$715.7M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	short runway, thin data, degenerate inputs not computable: distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Feb 11, 2026 240 days before the rescan; latest periodic filing 10-Q received Jul 29, 2026	
Last close	\$27.74 2026-10-08; market equity \$3.2B	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Feb 11, 2026

We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulintropic polypeptide, or GIP, receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. In March 2023, we announced the completion of the Phase 1 trial.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 41.1						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(10.0%)	(6.6%)	41.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 15.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		7.05	(0.31)	13.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		9.33x	2.96x	17.9	839	2025-12-31
Growth and financing, sleeve percentile 21.5						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		61.9%	2.1%	5.4	704	2025-12-31
Net share issuance, one year		2.9%	2.5%	37.6	634	2026-01-31

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.6 months
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	24.7%	8.0%	61
Distance from 52-week high	(34.2%)	(31.4%)	45
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.13	0.28	31
Sales to price	0.00	0.31	0
Composite equity issuance, five years	45.3%	20.3%	65
Relative strength against the sector, log excess return	0.01	(0.14)	61

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$125.8M
Operating cash flow, four quarters	-\$418.4M
Months of runway	3.6
Days since last periodic filing	72 (10-Q received Jul 29, 2026)
Median daily dollar volume, 63 sessions	\$66.7M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$359.6M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$278.7M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
3	assets	us-gaap:Assets	\$715.7M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
4	assets	us-gaap:Assets	\$908.3M	2024-12-31	2026-02-11	10-K	0001193125-26-046876
5	current assets	us-gaap:AssetsCurrent	\$715.6M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
6	current liabilities	us-gaap:LiabilitiesCurrent	\$76.7M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$847.5M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
8	operating income	us-gaap:OperatingIncomeLoss	-\$393.3M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
9	book equity	us-gaap:StockholdersEquity	\$639.1M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
10	liabilities	us-gaap:Liabilities	\$76.7M	2025-12-31	2026-02-11	10-K	0001193125-26-046876
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2025-12-31	2026-02-11	10-K	0001193125-26-046876
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2024-12-31	2026-02-11	10-K	0001193125-26-046876
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2023-12-31	2026-02-11	10-K	0001193125-26-046876
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2022-12-31	2025-02-26	10-K	0000950170-25-027824
15	assets	us-gaap:Assets	\$368.5M	2023-12-31	2025-02-26	10-K	0000950170-25-027824
16	assets	us-gaap:Assets	\$168.5M	2022-12-31	2024-02-07	10-K	0000950170-24-012322
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	115,554,295	2026-01-31	2026-02-11	10-K	0001193125-26-046876
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	112,247,809	2025-01-31	2025-02-26	10-K	0000950170-25-027824